<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> management (HGD) in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> remains controversial, in part, because of uncertainty about the ability of endoscopic biopsies to consistently detect early, curable <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Here we report <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> we have diagnosed in 45 patients with Barrett's HGD using a protocol involving serial endoscopies with four-quadrant biopsies taken at 1-cm intervals </plain></SENT>
<SENT sid="2" pm="."><plain>We compare these results to a modeled endoscopic biopsy protocol in which four-quadrant biopsies are taken every 2 cm in the Barrett's segment </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Thirteen <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> were detected at the baseline endoscopy and 32 in surveillance </plain></SENT>
<SENT sid="4" pm="."><plain>In 82% of patients, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was detected at a single 1-cm level of the esophagus, and in 69% the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was detected in a single endoscopic biopsy specimen </plain></SENT>
<SENT sid="5" pm="."><plain>A 2-cm protocol missed 50% of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> that were detected by a 1-cm protocol in Barrett's segments 2 cm or more without visible lesions </plain></SENT>
<SENT sid="6" pm="."><plain>The maximum depth of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> invasion was intramucosal in 96% of patients </plain></SENT>
<SENT sid="7" pm="."><plain>Only 39% of patients who had endoscopic biopsy <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnoses had <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> detected in the esophagectomy specimen </plain></SENT>
<SENT sid="8" pm="."><plain>Adverse outcomes included the development of regional <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> during surveillance (1 of 32), operative mortality (3 of 36), including two patients who had their primary surgeries at other institutions, and <z:hpo ids='HP_0011420'>death</z:hpo> from <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> after endoscopic ablation performed at another institution (1 of 3) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: A four-quadrant, 1-cm endoscopic biopsy protocol performed at closely timed intervals consistently detects early <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> arising in HGD in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and should be used in patients with HGD who do not undergo surgical resection </plain></SENT>
</text></document>